Takeda Pharmaceutical

TAKApproved

Founded in 1781, Takeda is a leading global biopharmaceutical company headquartered in Tokyo, Japan, with operations in over 80 countries. The company transformed through strategic acquisitions including Shire in 2019, building a diversified portfolio in oncology, rare diseases, neuroscience, and gastroenterology. Takeda focuses on developing breakthrough therapies while maintaining a strong commercial presence with blockbuster drugs generating billions in annual revenue.

Market Cap

$56.3B

Employees

45,000-50,000

Focus

Biotech

TAK · Stock Price

USD 17.83+2.90 (+19.42%)

Historical price data

AI Company Overview

Technology Platform

Takeda focuses on innovative drug discovery across oncology, rare diseases, neuroscience, and gastroenterology, with particular strength in cell and gene therapy platforms and specialty medicines for underserved patient populations.

Pipeline Snapshot

4 drugs in pipeline

Drug	Indication	Stage
Tislelizumab + Fruquintinib	Minimal Residual Disease	Phase 2
TIMP-GLIA + Placebo	Celiac Disease	Phase 2
Ramelteon 8 mg + Zopiclone 7.5 mg	Insomnia	Phase 1
TIMP-GLIA	Celiac Disease	Phase 1

FDA Approved Drugs

EOHILIANDAFeb 9, 2024

FRUZAQLANDANov 8, 2023

ENTYVIOBLASep 27, 2023

Opportunities

Takeda has significant growth opportunities through its robust pipeline in oncology and rare diseases, geographic expansion in emerging markets, and potential for strategic partnerships.

The integration of Shire's portfolio provides cross-selling opportunities and market expansion potential.

Risk Factors

Key risks include patent cliff for major products like Vyvanse, elevated debt levels from acquisitions requiring deleveraging focus, and competitive pressure in core therapeutic areas.

Pipeline execution and regulatory approval timelines present additional uncertainties.

Competitive Landscape

Takeda competes with global pharmaceutical giants like Roche, Novartis, and Johnson & Johnson in oncology, while facing specialized competition from BioMarin and Alexion in rare diseases. The company differentiates through its integrated approach, strong Asia-Pacific presence, and expertise in gastroenterology and rare diseases.

Publications

Pipeline

FDA Approvals